Glenmark Pharmaceuticals is a research-based pharmaceutical company specializing in product segments such as dermatology, internal medicine, pediatrics, gynecology, ENT and diabetes. The company in also engaged in researching new molecules and runs discovery projects in the areas of inflammation and metabolic disorders.
Glenmark’s decision to invest in this system is in line with our plans to build a robust US commercial sales front-end in a short time, to market generic products, said Terrance Coughlin, president of Glenmark Pharmaceuticals.
